Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172569937> ?p ?o ?g. }
- W2172569937 endingPage "50.e1" @default.
- W2172569937 startingPage "39" @default.
- W2172569937 abstract "PurposeTo analyze the value of novel measures of retinal pigment epithelium–drusen complex (RPEDC) volume to predict 2-year disease progression of intermediate age-related macular degeneration (AMD).DesignProspective, observational study.ParticipantsThree hundred forty-five AMD and 122 non-AMD participants enrolled in the Age Related Eye Disease Study 2 Ancillary Spectral-Domain (SD) Optical Coherence Tomography (OCT) study.MethodsHigh-density SD OCT macular volumes were obtained at yearly study visits. The RPEDC abnormal thickening (henceforth, OCT drusen) and RPEDC abnormal thinning (RAT) volumes were generated by semiautomated segmentation of total RPEDC within a 5-mm-diameter macular field.Main Outcome MeasuresVolume change and odds ratio (OR) with 95% confidence intervals (CI) for progression to advanced AMD with choroidal neovascularization (CNV) or central geographic atrophy (GA).ResultsComplete volumes were obtained in 265 and 266 AMD eyes and in 115 and 97 control eyes at baseline and at year 2, respectively. In AMD eyes, mean (standard deviation) OCT drusen volume increased from 0.08 mm3 (0.16 mm3) to 0.10 mm3 (0.23 mm3; P < 0.001), and RAT volume increased from 8.3 × 10−4 mm3 (20.8 × 10−4 mm3) to 18.4 × 10−4 mm3 (46.6 × 10−4 mm3; P < 0.001). Greater baseline OCT drusen volume was associated with 2-year progression to CNV (P = 0.002). Odds of developing CNV increased by 31% for every 0.1-mm3 increase in baseline OCT drusen volume (OR, 1.31; 95% CI, 1.06–1.63; P = 0.013). Greater baseline RAT volume was associated with significant 2-year increase in RAT volume (P < 0.001), noncentral GA (P < 0.001), and progression to central GA (P < 0.001). Odds of developing central GA increased by 32% for every 0.001-mm3 increase in baseline RAT volume (OR, 1.32; 95% CI, 1.14–1.53; P < 0.001). In non-AMD eyes, all volumes were significantly lower than AMD eyes and showed no significant 2-year change.ConclusionsMacular OCT drusen and RAT volumes increased significantly in AMD eyes over 2 years. These quantitative SD OCT biomarkers predict 2-year AMD progression and may serve as useful biomarkers for future clinical trials. To analyze the value of novel measures of retinal pigment epithelium–drusen complex (RPEDC) volume to predict 2-year disease progression of intermediate age-related macular degeneration (AMD). Prospective, observational study. Three hundred forty-five AMD and 122 non-AMD participants enrolled in the Age Related Eye Disease Study 2 Ancillary Spectral-Domain (SD) Optical Coherence Tomography (OCT) study. High-density SD OCT macular volumes were obtained at yearly study visits. The RPEDC abnormal thickening (henceforth, OCT drusen) and RPEDC abnormal thinning (RAT) volumes were generated by semiautomated segmentation of total RPEDC within a 5-mm-diameter macular field. Volume change and odds ratio (OR) with 95% confidence intervals (CI) for progression to advanced AMD with choroidal neovascularization (CNV) or central geographic atrophy (GA). Complete volumes were obtained in 265 and 266 AMD eyes and in 115 and 97 control eyes at baseline and at year 2, respectively. In AMD eyes, mean (standard deviation) OCT drusen volume increased from 0.08 mm3 (0.16 mm3) to 0.10 mm3 (0.23 mm3; P < 0.001), and RAT volume increased from 8.3 × 10−4 mm3 (20.8 × 10−4 mm3) to 18.4 × 10−4 mm3 (46.6 × 10−4 mm3; P < 0.001). Greater baseline OCT drusen volume was associated with 2-year progression to CNV (P = 0.002). Odds of developing CNV increased by 31% for every 0.1-mm3 increase in baseline OCT drusen volume (OR, 1.31; 95% CI, 1.06–1.63; P = 0.013). Greater baseline RAT volume was associated with significant 2-year increase in RAT volume (P < 0.001), noncentral GA (P < 0.001), and progression to central GA (P < 0.001). Odds of developing central GA increased by 32% for every 0.001-mm3 increase in baseline RAT volume (OR, 1.32; 95% CI, 1.14–1.53; P < 0.001). In non-AMD eyes, all volumes were significantly lower than AMD eyes and showed no significant 2-year change. Macular OCT drusen and RAT volumes increased significantly in AMD eyes over 2 years. These quantitative SD OCT biomarkers predict 2-year AMD progression and may serve as useful biomarkers for future clinical trials." @default.
- W2172569937 created "2016-06-24" @default.
- W2172569937 creator A5023633559 @default.
- W2172569937 creator A5047080761 @default.
- W2172569937 creator A5057740632 @default.
- W2172569937 creator A5058160578 @default.
- W2172569937 creator A5066264108 @default.
- W2172569937 creator A5090512897 @default.
- W2172569937 creator A5090802305 @default.
- W2172569937 date "2016-01-01" @default.
- W2172569937 modified "2023-10-16" @default.
- W2172569937 title "Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration" @default.
- W2172569937 cites W159419684 @default.
- W2172569937 cites W180947891 @default.
- W2172569937 cites W1965083039 @default.
- W2172569937 cites W1972642682 @default.
- W2172569937 cites W1974599215 @default.
- W2172569937 cites W1981111037 @default.
- W2172569937 cites W1990558727 @default.
- W2172569937 cites W1995478859 @default.
- W2172569937 cites W2000015918 @default.
- W2172569937 cites W2001080026 @default.
- W2172569937 cites W2002227479 @default.
- W2172569937 cites W2002437061 @default.
- W2172569937 cites W2011237852 @default.
- W2172569937 cites W2018243289 @default.
- W2172569937 cites W2027733533 @default.
- W2172569937 cites W2041137496 @default.
- W2172569937 cites W2060040689 @default.
- W2172569937 cites W2065895674 @default.
- W2172569937 cites W2066326071 @default.
- W2172569937 cites W2079413294 @default.
- W2172569937 cites W2080540990 @default.
- W2172569937 cites W2081268901 @default.
- W2172569937 cites W2093274680 @default.
- W2172569937 cites W2115773920 @default.
- W2172569937 cites W2127507482 @default.
- W2172569937 cites W2150472384 @default.
- W2172569937 cites W2156595418 @default.
- W2172569937 cites W2161462781 @default.
- W2172569937 cites W2318395464 @default.
- W2172569937 cites W2322965718 @default.
- W2172569937 cites W2330004533 @default.
- W2172569937 cites W2419255724 @default.
- W2172569937 cites W2609124342 @default.
- W2172569937 cites W3185739311 @default.
- W2172569937 cites W4252461477 @default.
- W2172569937 cites W4252865652 @default.
- W2172569937 doi "https://doi.org/10.1016/j.ophtha.2015.09.016" @default.
- W2172569937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26578448" @default.
- W2172569937 hasPublicationYear "2016" @default.
- W2172569937 type Work @default.
- W2172569937 sameAs 2172569937 @default.
- W2172569937 citedByCount "86" @default.
- W2172569937 countsByYear W21725699372016 @default.
- W2172569937 countsByYear W21725699372017 @default.
- W2172569937 countsByYear W21725699372018 @default.
- W2172569937 countsByYear W21725699372019 @default.
- W2172569937 countsByYear W21725699372020 @default.
- W2172569937 countsByYear W21725699372021 @default.
- W2172569937 countsByYear W21725699372022 @default.
- W2172569937 countsByYear W21725699372023 @default.
- W2172569937 crossrefType "journal-article" @default.
- W2172569937 hasAuthorship W2172569937A5023633559 @default.
- W2172569937 hasAuthorship W2172569937A5047080761 @default.
- W2172569937 hasAuthorship W2172569937A5057740632 @default.
- W2172569937 hasAuthorship W2172569937A5058160578 @default.
- W2172569937 hasAuthorship W2172569937A5066264108 @default.
- W2172569937 hasAuthorship W2172569937A5090512897 @default.
- W2172569937 hasAuthorship W2172569937A5090802305 @default.
- W2172569937 hasConcept C118487528 @default.
- W2172569937 hasConcept C142724271 @default.
- W2172569937 hasConcept C156957248 @default.
- W2172569937 hasConcept C2776403814 @default.
- W2172569937 hasConcept C2778024200 @default.
- W2172569937 hasConcept C2779093074 @default.
- W2172569937 hasConcept C2780827179 @default.
- W2172569937 hasConcept C2781359195 @default.
- W2172569937 hasConcept C71924100 @default.
- W2172569937 hasConceptScore W2172569937C118487528 @default.
- W2172569937 hasConceptScore W2172569937C142724271 @default.
- W2172569937 hasConceptScore W2172569937C156957248 @default.
- W2172569937 hasConceptScore W2172569937C2776403814 @default.
- W2172569937 hasConceptScore W2172569937C2778024200 @default.
- W2172569937 hasConceptScore W2172569937C2779093074 @default.
- W2172569937 hasConceptScore W2172569937C2780827179 @default.
- W2172569937 hasConceptScore W2172569937C2781359195 @default.
- W2172569937 hasConceptScore W2172569937C71924100 @default.
- W2172569937 hasIssue "1" @default.
- W2172569937 hasLocation W21725699371 @default.
- W2172569937 hasLocation W21725699372 @default.
- W2172569937 hasOpenAccess W2172569937 @default.
- W2172569937 hasPrimaryLocation W21725699371 @default.
- W2172569937 hasRelatedWork W2002437061 @default.
- W2172569937 hasRelatedWork W2259774676 @default.
- W2172569937 hasRelatedWork W2593747600 @default.
- W2172569937 hasRelatedWork W2790585032 @default.
- W2172569937 hasRelatedWork W2997098386 @default.